文献速递区域麻醉与超声疼痛医学术前评估与围术期医学

术前超声引导经皮冷冻神经消融治疗乳房切除术后疼痛的随机对照研究

Preoperative Ultrasound-guided Percutaneous Cryoneurolysis for the Treatment of Pain after Mastectomy: A Randomized, Participant- and Observer-masked, Sham-controlled Study.
PubMed 文献 · Anesthesiology · 2022-01-01

该随机、受试者与观察者设盲、假手术对照研究在乳房切除术前对同侧T2至T5肋间神经行超声引导经皮冷冻神经消融,主要终点为术后第2天疼痛评分。结果显示,与假手术组相比,冷冻神经消融组术后第2天疼痛评分显著降低,镇痛优势持续至第12个月,并降低阿片类药物用量和慢性疼痛发生率。

要点

  • 术后第2天疼痛中位数从假手术组3.0降至冷冻消融组0,差异有统计学意义。
  • 术后1至12个月无需口服镇痛药,慢性疼痛发生率从17%降至3%。
  • 前3周累积阿片类药物用量降低98%,未见全身副作用或并发症。

核心结论

  • 术前超声引导经皮冷冻神经消融可显著改善乳房切除术后镇痛,且无全身副作用或并发症。

研究设计与样本

  • 单中心随机、受试者与观察者设盲、假手术对照研究;冷冻消融组n=31,假手术组n=29,随访1年。

主要发现

  • 术后第2天疼痛评分冷冻消融组中位数0(四分位距0至1.4),假手术组3.0(2.0至5.0),差异-2.5(97.5%CI,-3.5至-1.5),P<0.001。
  • 前3周累积羟考酮用量冷冻消融组1.5(0至14)mg,假手术组72(20至120)mg,P<0.001,降低98%。
  • 术后1至12个月无患者需要口服镇痛药;1年时慢性疼痛冷冻消融组1例(3%),假手术组5例(17%),P<0.001。

临床怎么用

  • 乳房切除术前可考虑对同侧T2至T5肋间神经行超声引导经皮冷冻神经消融,作为多模式镇痛的一部分。
  • 该技术可能减少术后早期阿片类药物用量并降低慢性疼痛发生率,但需在有条件的中心开展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ultrasound-guided percutaneous cryoneurolysis is an analgesic technique in which a percutaneous probe is used to reversibly ablate a peripheral nerve(s) using exceptionally low temperature, and has yet to be evaluated with randomized, controlled trials. Pain after mastectomy can be difficult to treat, and the authors hypothesized that the severity of surgically related pain would be lower on postoperative day 2 with the addition of cryoanalgesia compared with patients receiving solely standard-of-care treatment. METHODS: Preoperatively, participants at one enrolling center received a single injection of ropivacaine, 0.5%, paravertebral nerve block at T3 or T4, and perineural catheter. Participants subsequently underwent an active or sham ultrasound-guided percutaneous cryoneurolysis procedure of the ipsilateral T2 to T5 intercostal nerves in a randomized, patient- and observer-masked fashion. Participants all received a continuous paravertebral block with ropivacaine, 0.2%, until the early morning of discharge (usually postoperative day 2). The primary endpoint was the average pain level measured using a 0 to 10 numeric rating scale the afternoon of postoperative day 2. Participants were followed for 1 yr. RESULTS: On postoperative day 2, participants who had received active cryoneurolysis (n = 31) had a median [interquartile range] pain score of 0 [0 to 1.4] versus 3.0 [2.0 to 5.0] in patients given sham (n = 29): difference -2.5 (97.5% CI, -3.5 to -1.5), P < 0.001. There was evidence of superior analgesia through month 12. During the first 3 weeks, cryoneurolysis lowered cumulative opioid use by 98%, with the active group using 1.5 [0 to 14] mg of oxycodone compared with 72 [20 to 120] mg in the sham group (P < 0.001). No oral analgesics were required by any patient between months 1 and 12. After 1 yr chronic pain had developed in 1 (3%) active compared with 5 (17%) sham participants (P < 0.001). CONCLUSIONS: Percutaneous cryoneurolysis markedly improved analgesia without systemic side effects or complications after mastectomy.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Ilfeld BM, Finneran JJ, Swisher MW, et al. Preoperative Ultrasound-guided Percutaneous Cryoneurolysis for the Treatment of Pain after Mastectomy: A Randomized, Participant- and Observer-masked, Sham-controlled Study. Anesthesiology. 2022. PMID: 35929983. doi:10.1097/ALN.0000000000004334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。